Outstanding work, @DrPatrick and @ImmunityBio Every step forward in cancer research brings renewed hope to families. Together,let’s keep advancing innovation and fighting to save lives.
$IBRX Let’s work toward giving more families hope and protecting more lives.
#Anktiva #Biotech
ImmunityBio’s momentum:
• ANKTIVA Q3 revenue up 53% YoY
• Expanded FDA approval and positive QUILT-2.005 results.
• Global authorization across 35 countries.
• Advancing NSCLC and Lynch syndrome programs.
Positive growth, regulatory progress and global expansion push $IBRX
12
What a great work you put in to see human survives cancer @DrPatrick @ImmunityBio. #Anktiva Let’s keep saving human race 💪💪 $ibrx #curecancer
This Post is from a suspended account. Learn more
16
IBRX retweeted
A dream coming into fruition, congratulations @ShyanneBatch
Treatment has started with @DrPatrick and the team at @ImmunityBio ($IBRX). It has been a JOURNEY to get to this place!
Grateful beyond words for everyone involved and all the angels here that helped advocate.
I can literally feel my entire immune system waking up. It's wild. The best I can hope is my story plays a role in expanding access for ALL patients that need these treatments. Won't stop until we get there.
What do you think? This is a lot of effort been put in by @DrPatrick His doing a great job 👏 #ibrx
At ASCO25, academia finally wakes up to what I've been saying for decades. "Every 10% decrease in ALC from baseline was associated with a 48% increase risk of death" Lymphocytes matter. The Cancer Bioshield protects. Can't wait to share with FDA this month.@DrPatrick
55
IBRX retweeted
ImmunityBio shared three announcements today:
· QUILT-2.005: ANKTIVA® plus BCG met the primary endpoint in Cohort A of the randomized BCG-naïve, high-grade NMIBC trial
· Israel Approval: ANKTIVA® plus BCG was approved for adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumors
· Q3 2026 & Global Progress: Net product revenue reached $48.7 million, up 53% year over year, alongside U.S. label expansion and an additional global approval
Read the full releases for complete information and important disclosures:
immunitybio.com/news-and-eve…
IBRX retweeted
ImmunityBio ranked No. 2 on the 2026 @Deloitte Technology Fast 500™, reflecting revenue growth of more than 47,000% from 2022 to 2025.
Thank you to our employees and partners for their contributions to this milestone.
Read the full announcement: immunitybio.com/immunitybio-…
$IBRX #fast500
IBRX retweeted
Last week, we honored our Veterans. Now, we’re listening to what they shared about the challenges of accessing #NMIBC care.
A new ImmunityBio survey conducted by @HarrisPoll found that 63% of veterans with NMIBC have faced treatment barriers, including long appointment waits (35%) and difficulty coordinating VA and non-VA care (27%).
These statistics represent delays and uncertainty for people who've already given so much. Researching and working to expand treatment options for patients with NMIBC is part of how we're working to change that.
Explore the full survey results: immunitybio.com/new-u-s-surv…
Inspiring to see patients receiving cellular therapies here in Riyadh. Looking forward to seeing future possibilities with our #BioShield at King Faisal Specialist Hospital & Research Centre #SaudiUSForum2025
@MISA @Saudi_FDA $IBRX investors
IBRX retweeted
Major League Volleyball (MLV), America’s longest-running indoor professional volleyball league, has announced ESPN as part of a landmark lineup of media relationships for its 2027 season, bringing together four networks overall to deliver more national exposure and expanded access to professional women’s volleyball.
Great start to the launch of Los Angeles Thunder @lathundervb
espnpressroom.com/press-rele…
$IBRX investors @DrPatrick is doing a great job to save human race.
This Post is from a suspended account. Learn more
1
62
At #SNO2026, Dr. Simon Khagi presented QUILT-3.078 in a rapid oral session, exploring the investigational combination of ANKTIVA® (N-803) + PD-L1 t-haNK cell therapy in recurrent glioblastoma.
Together, we’re advancing neuro-oncology research.
#Glioblastoma #NeuroOncology
At #SNO2026, Dr. Simon Khagi presented QUILT-3.078 in a rapid oral session, exploring the investigational combination of ANKTIVA® (N-803) + PD-L1 t-haNK cell therapy in recurrent glioblastoma.
Together, we’re advancing neuro-oncology research.
#Glioblastoma #NeuroOncology
1
74












